Takeda Pharmaceutical (TAK) Income towards Parent Company (2017 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Income towards Parent Company of $710.2 million for Q2 2026, down 17.29% year-over-year from $858.7 million in Q2 2025, and down 10.33% quarter-over-quarter from $792.0 million in Q1 2026.
Takeda Pharmaceutical (TAK) Income towards Parent Company (2017 - 2026) Analysis & Trends
Takeda Pharmaceutical's Income towards Parent Company history runs 10 years deep, the most recent figure standing at $710.2 million for Q2 2026.
- In Q2 2026, Income towards Parent Company fell 17.29% year-over-year to $710.2 million; the TTM figure through Jun 2026 stood at $574.3 million (down 76.16% YoY), while the FY2026 annual figure was -$1.0 billion, down 242.88% from the prior year.
- Income towards Parent Company for Q2 2026 stood at $710.2 million, down from $792.0 million in the prior quarter.
- The five-year high for Income towards Parent Company was $2.0 billion in Q3 2023, with the low at -$2.4 billion in Q4 2025.
- The 5-year median for Income towards Parent Company is $751.1 million (2026), against an average of $548.8 million.
- The sharpest annual moves came in 2023 and 2024: Income towards Parent Company jumped 912.2% in 2023, then slumped 422.64% in 2024.
- Takeda Pharmaceutical's Income towards Parent Company stood at $843.2 million in 2022, then sank by 75.05% to $210.4 million in 2023, then plunged by 422.64% to -$678.8 million in 2024, then slumped by 252.74% to -$2.4 billion in 2025, then soared by 129.66% to $710.2 million in 2026.
- Business Quant data shows TAK's Income towards Parent Company at $710.2 million in Q2 2026, $792.0 million in Q1 2026, and -$2.4 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - |
| 10 | Alkermes | 8.27 Bn | 7.61 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 710.19 Mn |
| Mar 31, 2026 | 791.97 Mn |
| Dec 31, 2025 | -2.39 Bn |
| Sep 30, 2025 | 1.47 Bn |
| Jun 30, 2025 | 858.66 Mn |
| Mar 31, 2025 | 814.08 Mn |
| Dec 31, 2024 | -678.83 Mn |
| Sep 30, 2024 | 1.42 Bn |
| Jun 30, 2024 | 611.86 Mn |
| Mar 31, 2024 | 642.39 Mn |
| Dec 31, 2023 | 210.40 Mn |
| Sep 30, 2023 | 1.98 Bn |
| Jun 30, 2023 | 652.31 Mn |
| Mar 31, 2023 | 793.80 Mn |
| Dec 31, 2022 | 843.22 Mn |
| Sep 30, 2022 | 447.05 Mn |
| Jun 30, 2022 | 812.01 Mn |
| Mar 31, 2022 | -97.73 Mn |
| Dec 31, 2021 | 508.22 Mn |
| Sep 30, 2021 | 417.54 Mn |